Media Library

The MalaFA CA (Malaria Futures for Central Africa supplementary report) is the latest extension of the Malaria Futures for Africa (MalaFA) study, commissioned by Novartis, which has already conducted similar research across 15 countries in Africa. The new supplementary report involved interviews with politicians, senior civil servants, malaria program directors, researchers and NGOs in Cameroon, Democratic Republic of the Congo (DRC), Republic of Congo, and Rwanda. All four are countries that have a significant malaria burden and differing policies in place to fight the disease. Study co-chairs are Dr Richard Kamwi, Ambassador, Elimination 8 (E8), and Professor Bob Snow, of the KEMRI-Wellcome Trust programme, Kenya and University of Oxford, United Kingdom.

Our stakeholders have important questions about our business practices in the United States, including our approach to price adjustments, patient assistance, investment in research and development, and marketing. The Novartis in Society US report aims to help answer those questions.

Our Annual Report 2019 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results.

This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also discloses our operating and financial results, accompanied by audited annual financial statements.

The Novartis in Society ESG Report details progress on environmental, social and governance topics and demonstrates the company’s commitment in global health and corporate responsibility.

Novartis is working on multiple fronts in the United States to build trust and expand access to healthcare in challenging times. The Novartis in Society US report details some of our initiatives in corporate responsibility, science & innovation, value & pricing, and responsible business practices.

The emotions surrounding an incurable disease like advanced breast cancer are profound and affect more than just the women living with the disease.

TSC symptoms and manifestations vary from person to person and may change over time.

Tuberous sclerosis complex (TSC) affects each person differently and manifestations can change over time, but most share TSC genetic threads in common.

RCC is the most common type of kidney cancer, accounting for up to 90% of cancerous kidney tumors.

Soft tissue sarcoma (STS) is a malignant tumor of connective tissue, accounting for about 1% of all human cancers.

Tuberous sclerosis complex (TSC) is a genetic disorder that may cause non-cancerous tumors to form in vital organs and can affect many parts of the body, including the brain, kidneys, heart, lungs and skin, with some patients exhibiting seizures, autism, cognitive delays or behavior issues.